Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

MGP Boards Questions > Molecular Genetic Nomenclature > Flashcards

Molecular Genetic Nomenclature Flashcards

1
Q

Which one of the following nomenclatures may be used to describe a functional, effective variant for MERRF?
A.c.8344A>G
B.g.8344A>G
C.m.8344A>G
D.n.8344A>G
E.r.8344A>G
F.p.8344A>G
G.None of the above

A

C.m.8344A>G

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Sanger sequencing of the TAZ gene on Xq28 for Barth syndrome was ordered. A C-to-G transversion in exon 5 was detected in John’s peripheral-blood sample, which was a nonsense mutation. Which one of the following nomenclatures may be used to describe this functional, effective variant?
A.c.153C>G
B.g.153C>G
C.m.153C>G
D.n.153C>G
E.r.153C>G
F.p.153C>G
G.None of the above

A

A.c.153C>G

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

By sequencing only the exons and 20-bp introns on either side of the exons, one variant of unknown clinical significance (VUCS) was found, which changed an aspartic acid (Asp/D) into tyrosine (Tyr/Y). Which one of the nomenclatures may Dr. Z use to describe this variant at the DNA level?
A.a.1268C>T
B.c.1268C>T
C.g.1268C>T
D.p.1268C>T
E.All of the above
F.None of the above

A

B.c.1268C>T

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

By sequencing only the exons and 20-bp introns on either side of the exons, one variant of unknown clinical significance (VUCS) was found, which changed an aspartic acid (Asp/D) into tyrosine (Tyr/Y). Which one of the nomenclatures may Dr. Z use to describe this variant at the amino acid level?
A.a.D401Y
B.c.D401Y
C.g.D401Y
D.p.D401Y
E.All of the above
F.None of the above

A

D.p.D401Y

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Which one of the following nomenclatures should be used to describe ACTTTGT[G]CC to ACTTTGT[GG]CC?
A.c.8dupG
B.c.8Gdup
C.c.8_9insG
D.c.8_9Gins
E.None of the above

A

A.c.8dupG

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

If an individual has a maternally inherited c.35delG in GJB2 and a paternally inherited c.14C>T in GJB6, which one of the following nomenclatures would be appropriate to use in the molecular report?
A.GJB2:c.35delG;GJB6:c.14C>T
B.GJB2:c.[35delG];GJB6:c.[14C>T] C.GJB6:c.14C>T;GJB2:c.35delG
D.GJB6:c.[14C>T];GJB2:c.[35delG]
E.A and C
F.B and D
G.None of the above

A

F.B and D

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Which one of the following nomenclatures is appropriate, according to HGVS?
A.c.IVS2+2T>G
B.LRG_1:g.8463-2G>C
C.c.88+2U>G
D.c.*46T>A
E.All of the above
F.None of the above

A

D.c.*46T>A

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Which one of the following nomenclatures may be used to describe a start codon, methionine (Met, M), is changed to valine (Val, V), which activates an upstream translation initiation site at position –12?
A.p.-12Met
B.p.-12Met1
C.p.-12Met1Val
D.p.Met1Valext-12
E.None of the above

A

D.p.Met1Valext-12

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Which one of the following nomenclatures may be used to describe a variant in the stop codon at position 110 of an amino acid sequence, changing it to a codon for glutamine (Gln, Q) and adding a tail of 17 new amino acids (including Gln/Q) to the protein’s C-terminus ending at a new stop codon?
A.p.110Glnext17
B.p.Ter110Glnext17
C.p.Ter110Gln
D.p.110GlnextTer17
E.p.*110Gln

A

A.p.110Glnext17

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Which one of the following nomenclatures may be used to describe a chimeric organism in which a chromosome in some cells contains a normal sequence (arginine, Arg/R) at position 83, while other cells contain another chromosome with serine (Ser/S) at this position?
A.p.[Arg83=/Arg83Ser]
B.p.[Arg83=//Arg83Ser]
C.p.[Arg83=];[Arg83Ser]
D.p.[Arg83=;Arg83Ser]
E.p.[Arg83=(;)Arg83Ser]
F.None of the above

A

B.p.[Arg83=//Arg83Ser]

chimerism is described using “//.”
Mosaicism is described using “/.”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Which one of the following nomenclatures may be used to describe a somatic mosaic case in which a chromosome in some cells contains a normal sequence (arginine, Arg/R) at position 83, while other cells contain a serine (Ser/S) at this position?
A.p.[Arg83=/Arg83Ser]
B.p.[Arg83=//Arg83Ser]
C.p.[Arg83=];[Arg83Ser]
D.p.[Arg83=;Arg83Ser]
E.p.[Arg83=(;)Arg83Ser]
F.None of the above

A

A.p.[Arg83=/Arg83Ser]

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Which one of the following nomenclatures may be used to describe two changes (amino acid alanine changes threonine at the position 25 and proline to leucine at the position 323, RNA or protein analyzed) were identified in one individual, but it is not known whether these changes are on the same chromosome (in cis) or on different chromosomes (in trans)?
A.p.[Arg83=/Arg83Ser]
B.p.[Arg83=//Arg83Ser]
C.p.[Arg83=];[Arg83Ser]
D.p.[Arg83=;Arg83Ser]
E.p.[Arg83=(;)Arg83Ser]
F.None of the above

A

E.p.[Arg83=(;)Arg83Ser]

two sequence changes in one gene with chromosomes unknown are described as “[change 1(;)change 2].” For example, p.[Ala25Thr(;)Pro323Leu] describes that two changes were identified in one individual (amino acid alanine-25 to threonine and proline-323 to leucine, RNA or protein analyzed), but it is not known whether these changes are on the same chromosome (in cis) or on different chromosomes (in trans).

p.[Ala25Thr];[Gly28Val] describes two changes derived from a gene on each chromosome (one paternal, one maternal);

If two independent changes in one individual are derived from one chromosome, they are described as “[first change;second change].” For example, p.[(Ala25Thr; Gly28Val)]

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Which one of the following nomenclatures may be used to describe a homozygous A-to-C change at the nucleotide position 76 of a cDNA?
A.c.[76A>C];[76A>C]
B.c.[76A>C];[(76A>C)]
C.c.[76A>C];[=]
D.c.[76A>C];[0]
E.None of the above

A

A.c.[76A>C];[76A>C]

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Which one of the following nomenclatures may be used to describe a heterozygous A-to-C change at the nucleotide position 76 of a cDNA?
A.c.[76A>C];[76A>C]
B.c.[76A>C];[(76A>C)]
C.c.[76A>C];[=]
D.c.[76A>C];[0]
E.None of the above

A

D.c.[76A>C];[0]

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Which one of the following nomenclatures may be used to describe a CHIMERIC case in which at position 83, in addition to the normal sequence (a G), some cells are found containing another chromosome containing a C at this position?
A.c.[83G=/83G>C]
B.c.[=/83G>C]
C.c.[83G=//83G>C]
D.c.[=//83G>C]
E.None of the above

A

D.c.[=//83G>C]

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Which one of the following nomenclatures may be used to describe a MOSAIC case in which at position 83, in addition to the normal sequence (a G), chromosomes are also found containing a C?
A.c.[83G=/83G>C]
B.c.[=/83G>C]
C.c.[83G=//83G>C]
D.c.[=//83G>C]
E.None of the above

A

A.c.[83G=/83G>C]

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Which one of the following nomenclatures is appropriate according to HGVS?
A.m.[76u>c]
B.m.[=,73_88del]
C.r.[76t>c]
D.r.[=,73_88del]
E.None of the above

A

C.r.[76t>c]

Mitochondrial DNAs are circulating DNAs in mitochondria, which are not diploid and do not contain U. So m.[=,73_88del] and m.[76u>c] are not correct.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Which one of the following nomenclatures is appropriate, according to recommendations for the description of RNA sequence variants published by the HGVS?
A.r.[88G>A]
B.r.[=,73_88del]
C.r.[76T>C]
D.r.[76t>c,73_88del]
E.None of the above

A

B.r.[=,73_88del]

“r.” is used to indicate that a change is described at the RNA level, and nucleotides are designated by the bases (in lower case).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

A reference sequence in the table below is mutated to … cag ATG [T]CC AAT CTT GCT AGC CCT AGA TTT GGT TCT … in a sample. Which one of the following nomenclatures is the most appropriate one to describe this change?
A.c.4C>T(p.2Ala>Ser)
B.c.4C>T(p.Ala2Ser)
C.c.C4T(p.Ala2Ser)
D.c.4C>T(a.2Ala>Ser)
E.None of the above

A

B.c.4C>T(p.Ala2Ser)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

A reference sequence in the table below is mutated to … cag ATG [T]CC AAT CTT GCT AGC CCT AGA TTT GGT TCT … in a sample. Which one of the following nomenclatures is the most appropriate one to describe this change?

A

C.c.4C>T(p.Ala2Ser)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

The patient had a C282Y and a H63D mutation in the HFE gene. Parental tests confirmed that the C282Y was from the mother, while H63D was from the father. Which one of the following nomenclatures is the most appropriate one for this patient?
A.p.H63D/C282Y
B.p.[H63D;C282Y]
C.p.[H63D];[C282Y]
D.p.[H63D(;)C282Y]
E.p.[H63D pat]+[C282Y mat]

A

C.p.[H63D];[C282Y]

59
Q

A technologist analyzed a peripheral-blood sample with an assay for hereditary hemochromatosis in a clinical molecular genetic laboratory. The patient had a C282Y and a H63D mutation in the HFE gene. Parental tests have not been done. Which one of the following nomenclatures is the most appropriate one for this patient?
A.p.H63D/C282Y
B.p.[H63D;C282Y]
C.p.[H63D];[C282Y]
D.p.[H63D(;)C282Y]
E.p.[H63D pat]+[C282Y mat]

A

D.p.[H63D(;)C282Y]

60
Q

A technologist analyzed a peripheral-blood sample with an assay for hereditary hemochromatosis in a clinical molecular genetic laboratory. The patient had a C282Y and a H63D mutation in the HFE gene. Parental tests confirmed that both C282Y and H63D were maternal in origin. Which one of the following is the most appropriate nomenclature?
A.p.H63D/C282Y
B.p.[H63D;C282Y]
C.p.[H63D];[C282Y]
D.p.[H63D(;)C282Y]
E.p.[H63D pat]+[C282Y mat]

A

B.p.[H63D;C282Y]

61
Q

Fragile X molecular testing was ordered for a 4-year-old boy with mental retardation. PCR and Southern blot methods were used for the analysis, and they detected one methylated allele with approximately 1000 CGG repeats. Which one of the following nomenclatures is the most appropriate to describe this change?
A.c.-129CGG[1000]
B.c.-129CGG(1000)
C.c.-129CGG[1000];[0]
D.c.-129CGG(1000);[0]
E.c.-129CGG(1000);(1000)

A

B.c.-129CGG(1000)

62
Q

A cystic fibrosis (CF) mutation panel was performed on a pregnant woman. The results showed an R117H mutation with a 5T allele. The parental tests confirmed that both of the variants were maternal in origin. Which one of the following nomenclatures is the most appropriate one to describe these changes?
A.c.[350G>A(;)1210-12T[5]]
B.c.[350G>A;1210-12T[5]]
C.c.[350G>A];[1210-12T[5]]
D.c.[350G>A];[(1210-12T[5])]
E.c.[350G>A(;)1210-12[5]]
F.c.[350G>A(;)1210-7_1210-6delTT]

A

B.c.[350G>A;1210-12T[5]]

63
Q

A cystic fibrosis (CF) mutation panel was performed on a pregnant woman. The results showed an R117H mutation with a 5T allele. The parental tests confirmed that R117H was maternal in origin while 5T was paternal in origin. Which one of the following nomenclatures is the most appropriate one to describe these changes?
A.c.[350G>A(;)1210-12T[5]]
B.c.[350G>A;1210-12T[5]]
C.c.[350G>A];[1210-12T[5]]
D.c.[350G>A(;)1210-12[5]]
E.c.[350G>A(;)1210-12[5]]
F.c.[350G>A;1210-12[5]]

A

C.c.[350G>A];[1210-12T[5]]

64
Q

A cystic fibrosis (CF) mutation panel was performed on a pregnant woman. The results showed an R117H mutation with a 5T allele. The parental tests have not been done. Which one of the following nomenclatures is the most appropriate one to describe these changes?
A.c.[350G>A(;)1210-12T[5]]
B.c.[350G>A;1210-12T[5]]
C.c.[350G>A];[1210-12T[5]]
D.c.[350G>A(;)1210-12[5]]
E.c.[350G>A(;)1210-12[5]]
F.c.[350G>A;1210-12[5]]

A

A.c.[350G>A(;)1210-12T[5]]

65
Q

A cystic fibrosis (CF) mutation panel was performed on a pregnant woman. The results showed a homozygous deltaF508 mutation. The parental tests have not been done. Which one of the following
A.c.[1521_1523delCTT];[1521_1523delCTT]
B.c.[1521_1523delCTT];[(1521_1523delCTT)]
C.c.[(1521_1523delCTT)];[(1521_1523delCTT)]
D.c.[1521_1523delCTT];[=]
E.c.[1521_1523delCTT];[0]
F.None of the above

A

B.c.[1521_1523delCTT];[(1521_1523delCTT)]

66
Q

A cystic fibrosis (CF) mutation panel was performed on a pregnant woman. The results showed a heterozygous deltaF508 mutation.Which one of the following nomenclatures is the most appropriate one to describe this change?
A.c.[1521_1523delCTT];[1521_1523delCTT]
B.c.[1521_1523delCTT];[(1521_1523delCTT)]
C.c.[(1521_1523delCTT)];[(1521_1523delCTT)]
D.c.[1521_1523delCTT];[=]
E.c.[1521_1523delCTT];[0]
F.None of the above

A

D.c.[1521_1523delCTT];[=]

76
Q

A reference sequence in the table below is mutated to … cag GGA GCC GCA [GCT] AGC CCT AGA TTT GGT TCT gtt tta … in a sample. Which one of the following nomenclatures is the most appropriate one to describe this change?
A.c.342_344del(p.Ala114del) B.c.343_345del(p.Ala114_Ala115delinsAla) C.c.343_345del(p.[Ala114=;Ala115del])
D.c.344_346del (p.Ala114_Ala115delinsAla) E.c.344_346del(p.[Ala114=;Ala115del]) F.c.345_347del(p.Ala115del)

A

F.c.345_347del(p.Ala115del)

77
Q

A reference sequence in the table below is mutated to … cag GGA GCC GCA GCG [GCT GCT] AGC CCT AGA TTT GGT TCT gtt tta … in a sample. Which one of the following nomenclatures is the most appropriate one to describe this change?
A.c.344_345insGCT(p.Ala114_Ala115insAla) B.c.347_348insGCT(p.Ala115_Ser116insAla) C.c.345dupGCT(p.Ala115dup) D.c.345_347dupGCT(p.Ala115dupAla)
E.None of the above

A

C.c.345dupGCT(p.Ala115dup)

78
Q

A reference sequence in the table below is mutated to … ca[a] ATG GCC AAT CTT GCT AGC CCT AGA TTT GGT TCT … in a sample. Which one of the following nomenclatures is the most appropriate one to describe this change?
A.c.-1G>A(p.Met1ext)
B.c.1-1G>A(p.-1fs)
C.c.-1G>A(p.-1fs)
D.c.-1G>A
E.None of the above

79
Q

A reference sequence in the table below is the last exon of a gene, which is mutated to … cag GGA GCC AAT CTT GCT AGC CCT AGA TTT GGT TAG [a]tt tga gca… in a sample. Which one of the following nomenclatures is the most appropriate one to describe this change?
A.c.+1G>A
B.c.362+4G>A(p.Ter121ext)
C.c.1G>A
D.c.365+1G>A
E.c.+1G>A(p.121ext?)

MGP Boards Questions (14 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions